News Daily News Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B Michael O'Riordan June 24, 2024
News Conference News ESC 2023 More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM Michael O'Riordan August 31, 2023
News Daily News New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF L.A. McKeown April 19, 2023
News Daily News As Amyloidosis Field Explodes, Physicians Need to Spot and Treat Todd Neale October 20, 2021
News Features ‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry Michael O'Riordan January 10, 2020